Tivanisiran improves discomfort, hyperemia in patients with dry eye
Posted in Uncategorized
VANCOUVER, British Columbia – Results from phase 2 and phase 3 trials showed that tivanisiran 1.125% significantly improved ocular discomfort/pain and conjunctival hyperemia in patients with dry eye and also confirmed its safety profile.
Ruz and colleagues from Sylentis, manufacturer of the small interfering ribonucleic acid (siRNA) inhibitor tivanisiran, conducted two multicenter, randomized, vehicle-controlled studies in six countries. SYL1001-II was the phase 2 trial, and Helix was phase 3.
According to the study, which was presented here at the Association for Research in Vision and …
Read More: Tivanisiran improves discomfort, hyperemia in patients with dry eye